While antigens for CAR-T cells in hematologic malignancies, most notably CD19 in B-cell malignancies and B-cell maturation antigen (BCMA) in multiple myeloma, are selectively expressed on target cancer cells and their cells of origin, targetable antigens in solid tumors are more elusive. The gene discussed is TNFRSF17; the disease is hematologic disorder.